期刊文献+

甘精胰岛素联合格列美脲与优泌乐25治疗2型糖尿病的疗效比较 被引量:5

下载PDF
导出
摘要 目的比较甘精胰岛素联合格列美脲与优泌乐25治疗口服降糖药未达标的2型糖尿病患者的疗效。方法 135例血糖控制未达标的2型糖尿病患者,随机分为甘精胰岛素联合格列美脲组(68例)与优泌乐25治疗组(67例),观察两组治疗前后血糖及HbAlc变化,以及低血糖的发生率。结果两组各监测点血糖及HbAlc,治疗后与治疗前比较均明显下降(P<0.01),治疗后两组间比较无明显差异;低血糖发生率无明显差异(P>0.05)。结论甘精胰岛素联合格列美脲与优泌乐25都能有效控制血糖,两组低血糖发生率低且相近。
作者 陈立
出处 《中国医学创新》 CAS 2011年第16期126-127,共2页 Medical Innovation of China
  • 相关文献

参考文献4

  • 1American Diabetes Association(ADA) guidelines:clinical practice rec-ommendations.Diabetes Care,2006,29(Suppl 1) S1.
  • 2Nathan DM,Buse JB,Davidson MB,et al.Management of hyperglyce-mia in type2 diabetes:A consensus algorithm for the initiation and ad-justment of therapy.Diabetes Care,2006,29(8):1963-1972.
  • 3Hirsch IB.Insulin analogues.N Engl J Med,2005,352:174.
  • 4Kann PH,Washcher T,Zackova V,et al.Staring insulin therapy intype 2 diabetes:twice-daily biphasic insulin aspart 30 plus metforminversus once-daily insulin glargine plus glimep iride.Exp Clin En-docrinol Diabetes,2006,114:527.

同被引文献58

  • 1卜石,郭晓蕙,杨文英,卢桂芝,杨兆军,任婷婷,高妍.预混胰岛素转为基础胰岛素联合口服降糖药治疗方案的2型糖尿病患者的临床特征分析[J].中华医学杂志,2007,87(44):3115-3118. 被引量:51
  • 2International Diabetes Federation. Diabetes Atlas (sixth edition). 2013.
  • 3IIag LL, Kerr L, Malone JK, et al. Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evident-based Comparison. Clin Ther, 2007, 29(6 pt1): 1254-1270.
  • 4Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract, 2008, 81(2): 184-189.
  • 5Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 Basal + Prandial Insulin Analogue Mixture with a Basal Insulin Analogue, Both Plus Metformin, in the Achievement of Target HbA1c and Pre- and Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes: A Multinational, 24-Week, Randomized, Open-Label, Parallel-Group Comparison. Clin Ther, 2007, 29(11): 2349-2364.
  • 6Kazda C, Hülstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications, 2006, 20(3): 145-152.
  • 7Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care, 2008, 31(1): 20-25.
  • 8Jain SM, Mao X, Escalante-Pulido M, et al. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes and Metab, 2010, 12(11): 967-975.
  • 9Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care, 2009, 32(6): 1007-1013.
  • 10Eli L. Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Who Consume a Light Breakfast. ClinicalTrials.gov[serial online] 2011 Nov 9 [cited 2013 Oct 24]. Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00664534?term=%E2%80%9Clispro%E2%80%9D+AND+%22glargine%22&rank=34§=Xd86015#outcome8.

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部